An open label study to evaluate the safety and reduction in signs and symptoms during treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis

Trial Profile

An open label study to evaluate the safety and reduction in signs and symptoms during treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 16 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 10 Aug 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
    • 20 Jun 2009 New source identified and integrated (Roche, ML22074).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top